MN660 Unit 4 mechanism of action paper example

Benzodiazepines Do Not Increase GABA: A Mechanism Paper From the Alpha-Gamma2 Interface Outward

[Student Name]

Purdue University Global

MN660: PMHNP Neuroscience and Psychopharmacology

Unit 4 Assignment

[Instructor Name]

[Date]

A model mechanism paper. No patient is described, and nothing here is clinical advice.

The Claim to Correct

Benzodiazepines are often said to "increase GABA." They do not raise the amount of GABA released. They change how the receptor responds to the GABA that is already there. The paper defends that more exact claim by describing the receptor first and the drug second.

Part 1: The Receptor

The GABA-A receptor is a chloride channel built from five subunits, most commonly two alpha, two beta and one gamma2. GABA binds at the interfaces between beta and alpha subunits. The benzodiazepine site lies elsewhere, at the interface between an alpha subunit and the gamma2 subunit. Consequence: receptors lacking gamma2, or containing an alpha subunit that does not form the site, do not respond to benzodiazepines.

Part 2: Positive Allosteric Modulation

A benzodiazepine bound at its site increases how often the channel opens when GABA is present. It does not open the channel on its own. Single-channel analysis showed that diazepam increases the frequency of channel opening, while barbiturates prolong each opening (Study & Barker, 1981). Consequence: because the drug amplifies GABA's own action rather than replacing it, its effect is limited by how much GABA is present, which underlies the relatively wide margin of benzodiazepines taken alone compared with barbiturates.

Part 3: Effects Sorted by Subunit

Knock-in mice, in which a single alpha subunit is altered so that it no longer binds benzodiazepines, have allowed effects to be assigned to subunits.

Alpha1: sedation, and part of the anticonvulsant and amnestic effects. Mice with insensitive alpha1 subunits were not sedated by diazepam but still showed reduced anxiety (Rudolph et al., 1999).

Alpha2: anxiety relief. Mice with insensitive alpha2 subunits lost diazepam's anxiety-relieving effect (Löw et al., 2000).

Alpha3: contributes to muscle relaxation and possibly some anxiety relief, in mouse studies.

Alpha5: learning and memory effects, in mouse studies.

The subunit data explain why sedation and anxiety relief come together with classic benzodiazepines, which bind all four subunits, and why drugs selective for alpha2 and alpha3 were pursued as anxiolytics without sedation. These attributions rest largely on mice; how exactly they carry over to humans remains incompletely established. Consequence: a patient taking a benzodiazepine for anxiety will usually also feel drowsy.

Part 4: Tolerance and Withdrawal

With continued use, the receptor adapts. Subunit expression shifts, and the coupling between the benzodiazepine site and the channel weakens, so the same dose produces less effect. When the drug is stopped, the adapted system is left with less inhibition than it had before treatment, which is felt as rebound anxiety, insomnia and, in severe cases, seizures. Consequence: tolerance to sedation often develops faster than tolerance to anxiety relief, and stopping after long use requires a gradual reduction.

Part 5: Flumazenil

Flumazenil binds the benzodiazepine site without changing the channel, displacing the benzodiazepine. It reverses sedation from benzodiazepines. Consequence: in a person dependent on benzodiazepines, abrupt displacement can precipitate withdrawal, including seizures, which limits its use.

Part 6: Combined Opioid Exposure

Benzodiazepines taken alone rarely stop breathing, because they only amplify GABA's action. Opioids depress breathing through a different mechanism, acting on mu-opioid receptors in brainstem respiratory centers. Together the effects add, and the margin that benzodiazepines have alone narrows sharply. In 2016 the FDA required boxed warnings on opioids and benzodiazepines about the risks of using them together (Food and Drug Administration, 2016). In 2020 it required a boxed warning for the whole benzodiazepine class addressing abuse, misuse, addiction, physical dependence and withdrawal (Food and Drug Administration, 2020). Both are regulatory consequences of the mechanism described in this paper.

References

Food and Drug Administration. (2016). FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning [Drug safety communication]. U.S. Food and Drug Administration.

Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class [Drug safety communication]. U.S. Food and Drug Administration.

Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., & Rudolph, U. (2000). Molecular and neuronal substrate for the selective attenuation of anxiety. Science, 290(5489), 131-134. https://doi.org/10.1126/science.290.5489.131

Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999). Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature, 401(6755), 796-800. https://doi.org/10.1038/44579

Study, R. E., & Barker, J. L. (1981). Diazepam and (-)-pentobarbital: Fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons. Proceedings of the National Academy of Sciences of the United States of America, 78(11), 7180-7184. https://doi.org/10.1073/pnas.78.11.7180